Radhika Tripurareni

VP, Medical Affairs

Back to Speakers

Prior to joining Prothena, Dr. Tripuraneni was Vice President, Medical Affairs at MyoKardia where she was responsible for the development of the global medical affairs strategy for mavacamten, a compound entering Phase 3 development for hypertrophic cardiomyopathy and MYK-491, in Phase 1 studies for dilated cardiomyopathy. Before MyoKardia she was Vice President, Medical Affairs at Synageva (which was acquired by Alexion), where she led a large global team of Medical Science Liaisons and supported the global launch of Kanuma, an FDA approved product for lysosomal acid lipase deficiency. Dr. Tripuraneni has experience across therapeutic areas in both orphan and non-orphan disease areas and has also worked in positions in Medical Affairs at Gilead and Genzyme, as well as in Corporate Development at Genzyme. Throughout her career she has demonstrated a commitment to science-led decision making and cross-functional collaboration that are hallmarks of our approach. Dr. Tripuraneni received her Bachelors’ in Business Administration (BBA) and Liberal Arts (BLA), Doctorate in Medicine (MD) from University of Missouri and her Master in Public Health (MPH) from Harvard University